Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volociximab in metastatic melanoma
NCT00369395Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Dec 2006
- Primary completion
- Mar 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of volociximab in melanoma, sponsored by Abbott Laboratories. Primary endpoint: Progression-Free Survival rate at 8 weeks. Started Dec 2006; status: terminated.
02
Drugs
volociximab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00369395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369395.